Skip to navigation Skip to content

High-risk neuroblastoma (NBL) Program in Pharmaceutical Benefits Scheme (PBS) 012-25070740

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised eflornithine for patients with high-risk neuroblastoma (NBL).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

High-risk neuroblastoma (NBL) quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB384 form

Written

Electronic

S85:

eflornithine

No

OPA

Must be treated in a hospital/cancer centre by a:

  • paediatric oncologist
  • haematologist

Yes

Grandfather

Telephone

Electronic

S85:

eflornithine

No

OPA

Must be treated:

  • in a hospital/cancer centre by a paediatric oncologist or a haematologist
  • by a medical practitioner under the direct supervision of a paediatric oncologist or a haematologist

Yes

Continuing

Telephone

Electronic

S85:

eflornithine

No

OPA

Must be treated:

  • in a hospital/cancer centre by a paediatric oncologist or a haematologist
  • by a medical practitioner under the direct supervision of a paediatric oncologist or a haematologist

Yes